New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareHexarelin vs Orforglipron

Hexarelin vs Orforglipron

Side-by-side comparison of key properties, dosing, and research.

Growth Hormone Peptides
Hexarelin
GLP-1 / Weight Loss Agonists
Orforglipron
Summary
Hexarelin is a potent synthetic GHRP and the strongest GH secretagogue in its class per unit dose. It also exhibits unique cardioprotective properties through direct binding to cardiac CD36 receptors, independent of GH release. Its potency is balanced by a tendency to desensitize GH release with prolonged use, making cycling important.
Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
Half-Life
~70 minutes
~12 hours (once-daily oral dosing)
Admin Route
SubQ
Oral
Research
Typical Dose
100–200 mcg
12 mg → 24 mg → 36 mg → 45 mg
Frequency
2–3 times daily
Once daily
Key Benefits
  • Strongest GH pulse per mcg among GHRPs
  • Unique direct cardioprotective effects via CD36
  • Increased IGF-1 and muscle anabolism
  • Accelerated recovery from training
  • Bone density support
  • Anti-aging via GH axis
  • Potential cardiac rehabilitation benefits
  • Oral pill — no injections required
  • Once-daily dosing without food restrictions (unlike oral semaglutide)
  • Up to 9.4% body weight reduction in Phase 2 at 36 weeks
  • Significant HbA1c reduction in type 2 diabetes trials
  • Small-molecule stability — no cold chain requirements
  • Broadens access for injection-averse patients
  • Potential class-defining convenience advantage over injectable GLP-1s
Side Effects
  • Water retention
  • Elevated cortisol
  • Elevated prolactin (more pronounced than other GHRPs)
  • Receptor desensitization with continuous use
  • +1 more
  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +2 more
Stacks With